ABSTRACT. Yesterday's immunodefideaeies emphasized t h e c~a n d t . m i l h l~~o f t h e s~m e s a n d date from the 1920s (ataxia-tehngktasia, chronic mum maneom cadidimis), tbe 1930s (Wiskott-Aldricb syn-
natural Liller cell defects associated with a) other primary immunodeficiencies, b) other nonimmp~)logic illness, and c) primary natud killer defects; 4) T-cell membrane defeets; 5) IL defects; and 6) miscelheoas pbgocytic illnesses including perkdontitis and the asplenia syndrome.
(Pedicrtr Rea 33 (Suppl): S2SS,1993) NK, natural killer TCR, T-cell receptor
The conventional wisdom concerning the birth of immunodeficiency is that this blessed event occurred in 1952 with Bruton's description of congenital agammaglobulinemia (1). In one respect this is true, in another, not so. Apmmaglobulinemia clearly was the tint i m m u n m c y described that necessitated an immunologic tea (in this case Tiselius' senun e l m phoresis) to iden* the disease and devise a treatment (gamma globulin injections). However, several phenotypic syndromes, now known to have major immunologic defects, were described many years before Bruton's report (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In this article, I review some historical papers on primary immunodeficiency (yesterday), discuss some trends in present day immunology (today), and project some d i s o h of immunity that will be forthcoming in the next several years (tomorrow).
Comspoadence: E. Richrd &hm, M.D., UCU ~eprtment of ~tdhtricq ucusch0olofMcdiciae,LorAaleles.CA90024.
si

YESTERDAY
Phenotypic syndromes were the first immunodeficiency syndromes described (Table l) A disorder of the phagocytic system was first identified in 1957 by the Minneapolis group, who described chronic granulomatous disease under the pessimistic name "fatal granulomatous disease of childhoodn (1 3). To complete the discovery of the main types of immunodeficiency, hereditary C2 deficiency with infection was first described in 1965 by Klemperer et al. (14) . References from Ross and Densen's marvelous review (15) of the comple ment deficiency syndromes provide the information necessary to construct a unique schema, the complement deficiency discovery pathway (Fig. l) 1973, 1980, 1989, and hopefully 1994 (1 8-2 1). The overall incidence of primary immunodeficiency probably has not changed in this two-decade period, remaining at about 1 per loo00 live births (excluding IgA deficiency).
However, a larger number of primary immunodeficiencies are recognized and more patients are surviving so that the total number of cases is increasing slowly. As the diverse cells and molecules of the immune system are identified and their interactions explored, more and more distinct disorders have been detined.
The secondary immunodeficiencies, those illnesses resulting from some nonimmunologic primary illness, have, by contrast, (Table 2 ). This means that investigtom discovend about two new primary and one new secondary immunodeficiencies annually. As the next edition will indicate, this discovery pattern continues unabated, involving all limbs of the immune system except for complement deficiencies, inasmuch as no new complement components have been added.
Some of the major areas of progress in the 6eld in the last two decades are identified in Table 3 . These include multiple new illnesses, new diagnostic techniques, and new and improved treatments, the latter including enzyme (polyethylene glycol-a adenosine deaminase) therapy, cytokine therapy, i.v. immune globulin, haploidentical bone marrow transplants, and gene thcrapy. New and better use of antibiotics and antiviral drugs hare also contributed to the better outlook for immunodeficient patients. Almost as i nas the new advances were the blind alleys. As noted in Table 4 , these include diagnoses that are in question (C5 dysfunction) or belong to a betterdehed syndrome (the patient with actin dysfunction had leukocyte adhesion deficiency) or have never been con6rmed. Certain treatments have been shown to be ineffective ( M e r factor) or replaced by better therapies (fetal liver transplantation). Some of these may be resurrected with M e r refinements (thymic hormone therapy) or under limited circumstances (IgA-deficient plasma for severe IgA sensitivity in a patient who needs immune globulin treatment). TOMORROW I have identified six new groups of immunodeficiencies ( Table  5 ) that are as yet unreported in my textbook, but that will be discussed in the next edition. Some of these disorders are new; others have been around for some time, but their description has not been recognized as part of the main stream of immunologic information. AIDS is another of tomorrow's immunodeficiencies, just as it is today's immunodeficiency. The number of papers on AIDS is increasing as rapidly as the spread of the epidemic; these efforts will continue to expand the knowledge of the cause and consequences of T-cell immunodeficiency.
The frrst group to be considered are the familial neutropenic syndromes with hypogammaglobulinemia as summarized in Table 6 . This table is derived from a recent article by Wetzler et al. (22) and includes their description of a new familial neutropenic syndrome: the WHIM syndrome. This is an illness described in two sisters (aged 22 and 23) who had Warts, Hypogammaglobulinemia,lnfections, and Myelokathexis, the latter referring to retention of leukocytes within a hypercellular marrow. Ig and B cells were low but not absent in the patients, and mitogeninduced proliferative responses and delayed hypersensitivity tests were somewhat decreased. The bone marrow was hypercellular with a shift to the right and many mature myeloid cells.
This and other hereditary immunodeficiencies with neutropenia emphasize the close relationship between the immune system and the control of myelopoiesis. Highdose i.v. immune globulin therapy often reverses the neutropenia in patients with X-linked agammaglobulinemia and the hyper-IgM syndrome. A unifylng hypothesis is sorely needed.
A second group of intriguing immunodeficiencies are the phenotypic genetic syndromes with immune abnormalities. Table 7 details several familiar and not so familiar syndromes that almost always have one or more immune defects. Bloom's syndrome and Schimke's immuno-osseous dysplasia are new amvals on this list and deserve some comment.
Bloom's syndrome (23-27) is an autosomal recessive syndrome of growth retardation, peculiar physiognomy, hypogonadism, and telangiectatic erythema of the face associated with sun sensitivity. There is a high frequency of chromosome breakage and increased risk for the development of lymphoid malignancy. Several papers have detailed the immunologic abnormalities associated with Bloom's syndrome, accounting for increased susceptibility to infection beginning early in life. These include 12-y-old male with Hodgkin's; 6-y-old brother has respiratory infection and adenopathy impaired proliferative responses to mitogens, decreased pokeweed mitogen-stimulated Ig synthesis in vitro, decreased responses in the mixed leukocyte reaction, diminished NK activity with normal NK cell number, slightly decreased serum Ig, and reduced CD4 T cells (23-27). Schimke's immuno-osseous dysplasia is an autosomal recessive skeletal dysplasia with dwarfism, progressive nephropathy, pigmentary skin changes, lymphopenia, and recurrent infections (28, 29). There is increased urinary excretion of chondroitin-6-sulfate in some patients. Immunologic abnormalities include decreased CD4 cells, decreased proliferative responses, decreased CD3 cells with an a/@ TCR, and thymic atrophy with abnormal NEW AND OLD &ah in tbe CJxdiak- 
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Tbacrll brve ddbdive T-cdl activation with poor poliftionofspedccytalrinca,nuwnumbmingd&k~S&ples. tuffsin deficiency is truly STIEHM rather than taking something that was known and then asking if there was a defect? Dr. Stiehm: You make a very good point. Initially, of course, clinical observations triggered the immunologic findings, as with agammaglobulinemia. Nowadays, most of the obvious syndromes have been discovered, and we are now reversing ourselves in finding the defects first and then finding a patient that has those defects.
Dr. Strober: Just a comment about primary NK-cell deficiency. Patients with X-linked immunodeficiency syndrome, for instance, very frequently have reduced NK function, and when you look at these patients, they have very poor lymphokine production. It is probable that this is a secondary phenomenon. I feel that the burden of proof is on us to show that there is really a primary NK-cell deficiency, rather than one that is secondary to some much more broadly based abnormality.
Dr. Levy: In my experience, it seems that the chronic fatigue syndrome is a real entity, but I think it is going to turn out to be a mixed bag. The current Annals of Internal Medicine includes an analysis of the Lake Tahoe epidemic of chronic fatigue syndrome, which was originally billed as an EBV (Epstein-Barr virus) infection but later turned out not to be. Robert Gallo, whose name is on the paper, claims to have grown out herpes virus 6 (HHV-6) from a very large percentage of the cells of those patients; whether that is causative or secondary is unclear.
Dr. Frank: What was reported was an abnormality of cells that looked like they were infected by HHV-6, but were actually large macrophages. Before we get canied away with HHV-6, we should beware of 0bSe~ationS which are reported on a morphologic basis rather than on real serologic information.
Dr. Levy: The authors did not make the claim that it was causative. In my former position, in the Laboratory of Clinical Investigation, Steve Straw admitted a fair number of patients with chronic fatigue syndrome, and it was clear that those patients had something. What they have is very unclear, but I think it would be premature to dismiss chronic fatigue syndrome as simply a psychiatric disorder.
